1 completed, 1 terminated, 1 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Syndesi Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline SDI-118, Placebo - Cognitive Decline | Phase 1 | Terminated | Syndesi Therapeutics | 5 | 2021-09-23 | 2022-04-22 |
| A Study of SDI-118 in Participants in Remission From Depression SDI-118, Placebo - Depression in Remission | Phase 1 | Withdrawn | Syndesi Therapeutics | 2021-09-16 | 2022-04-22 | |
| A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect SDI-118, Placebo - Cognitive Disorders | Phase 1 | Completed | AbbVie | 32 | 2019-03-14 | 2022-08-03 |
Cognitive Dysfunction (2) · Depression (1) · Depressive Disorder, Major (1)
United Kingdom (2) · Belgium (1) · Germany (1)
Katharine Smith, DM (1) · Maeve Duffy, PhD (1)
2018 (1)